| To stop or not to stop? How long should medication treatment of attention-deficit hyperactivity disorder be extended? | |
| | |
MedLine Citation:
|
PMID: 21530185 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
ADHD is a common neuropsychiatric disorder with a strong persistence over time. Medication is frequently used in the clinical management of ADHD. After response, medication is typically prescribed for months to years. It is unclear whether extended medication treatment provides long-term benefits and how long it should be continued. Furthermore, there is concern about the long-term safety of ADHD medication. The aim of this systematic review is to address these issues and provide recommendations about the decision to stop or not to stop ADHD medication. We performed a search in PubMed and focused on medication studies with a treatment longer than 12weeks in subjects 6-18years old. Extended placebo-controlled double-blind parallel studies are not available. Placebo-controlled discontinuation studies and prospective long-term observational treatment studies provide evidence that medication management leads to a substantial reduction of ADHD symptoms and less impairment of functioning for a period of about 2years. There is limited and inconsistent evidence for long-term advantage of medication treatment beyond symptom control, such as improved social functioning, academic achievement, employment status and less adverse psychiatric outcome. In terms of safety, long-term effects of medication on growth, blood pressure and heart rate are limited and the occurrence of suicidal, psychotic and manic symptoms is rare. Animal data about neurotoxic effects of psycho stimulants cannot be directly extrapolated to humans. Therefore, clinical decisions about starting, continuing, and stopping of ADHD medication should be made on an individual basis. Medication free periods should be implemented at regular times to investigate the need for an ongoing benefit of medication. Unfounded assumptions about continuing benefit of medication use should be abandoned. Careful monitoring of side effects is necessary and must be able to detect early alarming signals. |
| | |
Authors:
|
Gigi H H van de Loo-Neus; Nanda Rommelse; Jan K Buitelaar |
Related Documents
:
|
15801175 - Analysis of pellets found in the north area of the asiago plateau (vicenza, italy), a l... 21358565 - Leadership in medical emergencies depends on gender and personality. 21472145 - Improving medication adherence in chronic disease management. 22060235 - Patients' experience of hospital pharmaceutical services. 18702355 - Fine needle aspiration cytology in nigeria. 10284595 - Focus on: biomedical engineering department, saint therese medical center. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-4-27 |
Journal Detail:
|
Title: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology Volume: - ISSN: 1873-7862 ISO Abbreviation: - Publication Date: 2011 Apr |
Date Detail:
|
Created Date: 2011-5-2 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9111390 Medline TA: Eur Neuropsychopharmacol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
Copyright © 2011 Elsevier B.V. and ECNP. All rights reserved. |
Affiliation:
|
Karakter Child and Adolescent Psychiatry University Centre, Nijmegen, Netherlands. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Post-exposure therapy of inhalational anthrax in the common marmoset.
Next Document: Electrochemical behaviour of carbon paste electrodes enriched with tin oxide nanoparticles using vol...